Reply to Clarification- Financial results

Date: 22 July 2026 The Manager – Listing Compliance National Stock Exchange of India Limited Mumbai Subject: Clarification on Variations Observed between XBRL Submission and PDF Financial Results – Bal Pharma Limited Dear Sir/Madam, This is with reference to your emails dated 22 June 2026, 02 July 2026 and 20 July 2026, seeking clarification regarding the variations observed between the financial results submitted in XBRL format and the corresponding PDF financial statements of the Company, particularly in respect of Standalone Profit After Tax (PAT), Standalone Earnings Per Share (EPS), and the Standalone and Consolidated Cash Flow Statements. We sincerely thank you for bringing the matter to our attention. In this regard, we wish to clarify that the financial results approved by the Board of Directors and reviewed/audited by the Statutory Auditors, as contained in the PDF financial results submitted earlier, represent the final and correct financial results of the Company. Upon review of the matter, we have identified that the variations observed in the earlier XBRL submissions were attributable to certain technical and validation-related aspects of the XBRL filing utility, including the manner in which certain figures and derived values were captured and rounded off during the filing process. To address the discrepancies and ensure consistency between the XBRL filings and the financial results submitted in PDF format, the Company has refiled the Standalone and Consolidated Financial Results in XBRL format. We confirm that the revised XBRL submissions have been duly aligned with and now match the corresponding figures reported in the PDF financial results submitted earlier. Accordingly, we confirm that: 1. There has been no change or revision in the financial results approved by the Board of Directors of the Company. 2. The financial results contained in the PDF financial statements submitted earlier remain the final and approved financial results of the Company. 3. The Standalone and Consolidated XBRL financial results have been refiled to rectify the earlier technical variations, and the figures reported in the revised XBRL filings are now matching with the corresponding PDF financial results submitted earlier. 4. The revised XBRL filings represent the same underlying financial information as contained in the approved PDF financial results, and there is no inconsistency in the financial results approved by the Board of Directors. 5. The Company has reviewed the filing process internally and shall exercise additional care in future filings to ensure that the XBRL submissions are duly reconciled with and aligned to the signed and approved financial statements. In view of the above, we request you to kindly take the revised XBRL filings and the above clarification on record and oblige. Thanking you. Yours faithfully, For Bal Pharma Limited Shreepada M L Company Secretary & Compliance Officer Enclosure: PDF File – Financial Result as outcome of Board meeting Corporate Office © +9180 4137 9500 BAL PHARMA LIMITED © info@batpharma.com oO Sth Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India. 27.05.2026 The Manager-Listing BSE Limited Mumbai. National Stock Exchange of India Ltd Mumbai. Dear Sir, Sub : Outcome of the Board Meeting Ref: Regulation 29 of SEBI(LODR) Regulations, 2015. With reference to the above, Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Audited standalone and consolidated financial results of the Company for the quarter and financial year ended 31.03.2026. A copy of the approved financial results together with the audit report issued by the statutory auditors of the Company with unmodified opinion is enclosed with this intimation. 2 Recommended dividend of Re.1.20/- per equity share of Rs.10/- each i.e 12 %, which is subject to the approval of members at the ensuing Annual General Meeting of the Company. 3.Appointed Murugesh & Co, Chartered Accountants as Internal Auditors, G.N.V & Associates , Cost Accountants as Cost Auditors for the financial year 2025.26. 4. Approved grant of 5,00,000 stock options to the employees of the Company under “Bal Pharma Limited — Employee Stock Option Plan-2025”, 5. Approved preferential issue of 10,00,000 warrants to the promoters of the Company at the applicable conversion price. 6. Decided to seek shareholders approval for preferential issue of warrants through postal ballot. 7. Approved appointment of Mr. Shreepada ML ( M # A66681) as Company Secretary and Compliance officer of the Company. Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Karnataka, INDIA. Ph: +91 80 41570811/813. CIN # L85TIOKAI987PLCO008368 6) www.balpharma.com Corporate Office © +9180 4137 9500 BAL PHARMA LIMITED © info@baipharma.com 2 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India. | Page-2 Details with respect to the appointment of Company Secretary as per SEBI Circular No. CIR/ CFD/ CMD/4/2015 dated 9th September 2015 is enclosed as Annexure-1 The Meeting commenced at 4.30 p.m and concluded at 5.30 p.m on 27.05.2026. Please take this intimation on record. Shailesh Siroya Managing Director Annexur—e I Disclosure required under Listing Regulations read with SEBI Circular No. CIR/ CFD/ CMD/4/2015 dated 9th September 2015, are as under:- SI No Particulars Details 01 Reason for change viz. appointment; | Mr. Shreepada is appointed resignation, remdeoath vor aothelrwi se as Company Secretary and Compliance officer of the Company in place of Mr.Abdul Basith who has tendered his resignation w.e.f 11.05.2026. 02 Date of appointment/eessatien—(a s applicable) | 27.05.2026 & term-ofappoimtment 03 Brief profile (in case of appointme nt) Mr.Shreepada is Company Secretary by profession with over 7 years of experience in various industries. Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099, Karnataka, INDIA. Ph: +91 80 41570811/813. CIN # L85TIOKAI987PLCO08368 6? www.balpharma.com Corporate Office © +9180 4137 9500 BAL PHARMA LIMITED © info@balpharma.com @ 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India. 27.06.2026 The Manager-Listing National Stock Exchange of India Ltd Mumbai. BSE Limited Mumbai. Dear Sir, Sub: Declaration of Unmodified Opinion on Audited Financial Results for the quarter and Financial year ending 31.03.2026. Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations , 2015, we hereby declare and confirm that the statutory auditors of the Company VIZ.SSJNB & Co, Chartered Accountants , having membership # 00139768 have issued their limited review report with Unmodified opinion on audited Standalone and Consolidated Financial results of the Company , for the quarter and financial year ended 31" March 2026. Please take this intimation on record. For Bal Pharma Limited Shailesh Siroya Ks / Managing Director “fiz; hy Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Karnataka, INDIA. Ph: +91 80 41570811/813. CIN # L85TIOKAI987PLCO08368 6) www.balopharma.com SSJNB&Co f >% « . ee WO Chartered Accountants INDIA Landline: 080-4977 79/ 552/513/5 4 Email: office@ssjnb.in INDEPENDENT AUDITOR’S REPORT ON AUDIT OF QUARTERLY AND ANNUAL STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF BAL PHARMA LIMITED Opinion We have audited the accompanying Statement of Standalone Financial Results (the “Statement”) of Bal Pharma Limited (the “Company”), for the quarter and year ended March 31, 2026, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations’). In our opinion and to the best of our information and according to the explanations given to us, the Stat [Showing first 8,000 characters — download PDF for full document]